Early Target Attainment With Continuous Infusion Meropenem and Piperacillin/Tazobactam and Utilization of Therapeutic Drug Monitoring in Critically Ill Patients: A Retrospective Cohort Study From 2017 to 2020.

ABSTRACT:

Background

We analyzed the attainment of early pharmacological targets of continuous infusion meropenem and piperacillin/tazobactam and the use and effect of a real-time therapeutic drug monitoring (TDM) program on subsequent dosing and target attainment in patients who are critically ill.

Methods

This was a single-center, retrospective study among patients hospitalized in the intensive care unit in a Swiss tertiary care hospital from 2017 to 2020. The primary outcome was target attainment [100% tT _{≥ 4xECOFF (Pseudomonas aeruginosa)}] of continuous infusion meropenem and piperacillin/tazobactam within 72 hours after initiation of treatment.

Results

A total of 234 patients were included. Median first meropenem (n = 186 of 234) and piperacillin (

SUBMITTER: Drager S 

PROVIDER: S-EPMC10109529 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature